Table 2.
Available guidelines on the preventive therapy for DR-TB contacts.
| Source | Year of Publication | Population Addressed | Recommendation to Treat | Watchful Observation Approach | Drug | Ancillary Drugs | Treatment Duration |
|---|---|---|---|---|---|---|---|
| WHO | 2020 | General | Yes | Consider | Lfx | E, Eth | 6 months |
| ECDC | 2012 | General | Yes | Consider | Lfx | No | 6 months |
| ATS/CDC/ ERS/IDSA |
2019 | General | Yes | Not recommended | Lfx | No | 6–12 months |
| MSF | 2022 | Pediatric | Yes | Consider | Lfx | No | 6 months |
Abbreviations: WHO, World Health Organisation; ECDC, European Centre for Disease Prevention and Control; ATS, American Thoracic Society; CDC, U.S. Centers for Disease Control and Prevention; ERS, European Respiratory Society; IDSA, Infectious Diseases Society of America; MSF, Doctors Without Borders; Lfx, levofloxacin, E, ethambutol and Eth, ethionamide.